|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Overruled: No More Dual Pricing
Author(s)Kevin Gopal
European Union-The European Commission’s ban on GlaxoSmith–Kline’s dual pricing policy in Spain halts one of Big Pharma’s attempts to prevent parallel imports in Europe.
Advertisement
Articles in this issue
almost 25 years ago
Pharmacies: OTC Price Warsalmost 25 years ago
One Disease at a Timealmost 25 years ago
Overview of the Industry: A World of Opportunitiesalmost 25 years ago
The Power Shiftalmost 25 years ago
A Giant Stumblesalmost 25 years ago
Submergedalmost 25 years ago
Generic ThreatAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It
2
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma
3
The New Healthy Aging Imperative and What It Means for Pharma
4
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
5